0001127602-24-001603.txt : 20240118 0001127602-24-001603.hdr.sgml : 20240118 20240118165506 ACCESSION NUMBER: 0001127602-24-001603 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240117 FILED AS OF DATE: 20240118 DATE AS OF CHANGE: 20240118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eisele Jeffrey CENTRAL INDEX KEY: 0001827326 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 24542476 MAIL ADDRESS: STREET 1: APELLIS PHARMACEUTICALS, INC. STREET 2: 100 5TH AVENUE, 3RD FLOOR CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-977-5700 MAIL ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2024-01-17 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001827326 Eisele Jeffrey C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR WALTHAM MA 02451 1 Chief Development Officer 1 Common Stock 2024-01-17 4 S 0 5207 65.58 D 67443 D This is a scheduled sale from an established 10b5-1 plan. /s/ David Watson, attorney-in-fact for Jeffrey Eisele 2024-01-18